Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of early pregnancy location and viability compared with hCG, progesterone and estradiol

Research output: Contribution to journalJournal articleResearchpeer-review

  1. HLA-DRB1 polymorphism in recurrent pregnancy loss: New evidence for an association to HLA-DRB1*07

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Soluble HLA-G and TGF-β in couples attending assisted reproduction - A possible role of TGF-β isoforms in semen?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Plasma YKL-40 during pregnancy and gestational diabetes mellitus

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Phenotypic characterisation of immune cell infiltrates in testicular germ cell neoplasia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A systematic review and meta-analysis on the association between ICSI and chromosome abnormalities

    Research output: Contribution to journalReviewResearchpeer-review

  2. Parenthood among men diagnosed with cancer in childhood and early adulthood: trends over time in a Danish national cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

A circulating biomarker of early pregnancy outcome independent of ultrasonography and gestational age is a coveted goal. This study evaluated soluble urokinase plasminogen activator receptor (suPAR), a well-described marker of inflammation and immunological activation, for this purpose, and compared it with established early pregnancy biomarkers of the luteoplacental phase: progesterone, estradiol and hCG. We merged data from two prospective first trimester cohorts to conduct a case-control study comparing these analytes in women who had either a live birth, a miscarriage or an ectopic pregnancy. The ability to predict pregnancy location and viability was assessed by areas under the receiver operating characteristic curves (AUC). Comparing women irrespective of gestational age with a live birth, miscarriage or ectopic pregnancy showed significantly lower suPAR values in the latter group (2.4 vs. 2.4 vs. 2.0 μg/L, p = 0.032, respectively), as were all other analytes. Before 6 weeks' gestation, suPAR was significantly inferior to progesterone, estradiol and hCG in pregnancy location and viability prediction (in 124 pregnancies, suPAR AUClocation = 0.69 [CI: 0.54-0.83] and AUCviability = 0.58 [CI: 0.48-0.69], while progesterone AUClocation = 0.95 [CI: 0.87-1.00] and AUCviability = 0.84 [CI: 0.75-0.92]). After 6 weeks' gestation, suPAR prediction improved but was inferior to hCG, progesterone and estradiol (in 188 pregnanices, suPAR AUClocation = 0.71 [CI: 0.63-0.78] and AUCviability = 0.70 [CI: 0.63-0.78] compared with hCG AUClocation = 0.96 [CI: 0.93-0.99] and AUCviability = 0.96 [CI: 0.93-0.98]). Collectively, suPAR is less useful as a predictor of early pregnancy outcome than hCG, progesterone and estradol.

Original languageEnglish
JournalJournal of Reproductive Immunology
Volume138
Pages (from-to)103103
ISSN0165-0378
DOIs
Publication statusPublished - Apr 2020

    Research areas

  • Early pregnancy, Ectopic pregnancy, Live birth, Progesterone, suPAR

ID: 59518054